MungmunpuntipantipR, WiwanitkitV. Timing of tocilizumab use and COVID-19. Respir Care, 2022; 67(3):381-382.
2.
SinghAK, OksM, HuskG, DecharioSP, MinaB, SinghK, et al. Impact of tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir Care, 2021; 66(12):1805-1814.
3.
PadwalMK, MurshidM, NirmaleP, MelinkeriRR. Association of serum ferritin levels with metabolic syndrome and insulin resistance. J Clin Diagn Res, 2015; 9(9):BC11-3.
4.
Gomez-PastoraJ, WeigandM, KimJ, WuX, StrayerJ, PalmerAF, et al. Hyperferritinemia in critically ill COVID-19 patients - is ferritin the product of inflammation or a pathogenic mediator?. Clin Chim Acta, 2020; 509:249-251.
5.
MilicJ, BanchelliF, MeschiariM, FranceschiniE, CiusaG, GozziL, et al. The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. PLoS One, 2021; 16(8):e0251378.
6.
GriffinDO, Brennan-RiederD, NgoB, KoryP, ConfalonieriM, ShapiroL, et al. The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev, 2021; 23(1):40-47.
